Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK

Table 1 Change in outcomes pre- to post-treatment

Outcome	n	Pre-treatment Median (IQR)	Post-treatment Median (IQR)	Change Median (95% CI)	p-value
Headache days	254	27 (22, 30)	18 (10, 25)	-7 (-8, -5)	<0.001
Migraine days	254	15 (10, 19)	7 (3, 12)	-6 (-8, -5)	<0.001
Crystal clear days	254	3 (0, 8)	12 (5, 20)	7 (5, 8)	<0.001
Mild days	254	10 (7, 15)	8 (4, 13)	-1 (-2, -1)	<0.001
Painkiller days	242	12 (7 ,20)	6 (2, 12)	-3 (-4, -3)	<0.001
Triptan days	241	5 (0, 8)	2 (0, 6)	0 (-1, 0)	<0.001
Days off work	58	4 (3, 6)	1 (0, 4)	2 (3, 1)	<0.001

The analysis suggested statistically significant differences between the pre-and post- treatment measurements for all outcomes examined. Headache days, migraine days, mild days, painkiller days, triptan days and days off work were all found to be significantly reduced after compared with before treatment. For example, the median number of headache days was 27 before treatment reduced to 18 after treatment (p < 0.001). Conversely, there was a significant increase in the number of headache free days from pre- to post-treatment (3 to 12 days respectively) (p < 0.001).

ISSN: 1129-2377